Braveheart Bio
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 1 year.
- Recent price momentum is -25.6% on average (3-month/1-year).
- Main-fund capital flow has been a net inflow over the last 45 sessions.
- Short interest has risen to 5.7% of float.
- Analyst tilt is Buy.
- Price is above its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Performance
Key statistics
Price & volume
- Prev close
- 19.27
- Open
- 19.29
- Day range
- 18.83 - 21.16
- Avg price
- 20.35
- Volume
- 866.73K
- Turnover
- 17.64M
- Turnover ratei
- 4.62%
- Volume ratioi
- 1.07
- Amplitudei
- 12.12%
- 52-week rangei
- 16.70 - 32.00
Valuation
- P/Ei
- -21.81
- P/E (TTM)i
- -27.82
- P/Bi
- 3.68
- EPSi
- -0.94
- Book value / shi
- 5.54
- Net profit
- -84.03M
- Net assets
- 497.61M
Share structure
- Market cap
- 1.83B
- Float capi
- 382.31M
- Shares out
- 89.87M
- Float sharesi
- 18.75M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2026-08-06
36.3% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
+1.83M net over the window
Short interest
- Shares short
- 5.15M
- % of floati
- 5.72%
- Days to coveri
- 19.63
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Braveheart Bio (BRVE)?
Braveheart Bio last traded at 20.39. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Braveheart Bio's market cap?
About 1.83B.
What is the P/E ratio of Braveheart Bio?
The trailing twelve-month P/E is -27.82. The Valuation tab shows it against the stock's own five-year range.
Does Braveheart Bio pay a dividend?
Braveheart Bio does not currently pay a regular dividend.
Is Braveheart Bio a buy according to analysts?
The consensus of 5 analysts is a Buy rating, with an average 12-month price target of 45.50, which implies 123.1% upside from the current price. This is not investment advice.
What is Braveheart Bio's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Braveheart Bio a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Braveheart Bio discussion 0 comments